Gh'è diverse opzion de cura per el cancer de prostata, a segonda del stadi e de l'aggressività del cancer, inscì cuma de la salute general e di preferenz personai del pazient.
Un quai tratament comun a inn:
1. Sorveglianza ativa: Chestu approcch al implica un monitoragg strett del cancher cun control e test regolàr, inveci de cumincià subit el trattament.
Pœu l"è adat per i òmen cun un cancer de prostata a ris'c bass.
2. Chirurgia: Una prostatectomia l"è una procedura chirurgica per eliminà la ghiandola prostatica.
La pœl vesser fada cont una chirurgia avert o laparoscopica (usand piccole incisiun e strument speciai).
3. Radioterapia: chesta cura la dupera radiaziun de alta energia per copà i cellule cancerose.
El pœl vesser somministrad esternament (da una machina fœra del corp) o internament (a travers di impiant metud arent al tumur).
4. Terapia ormonale: chestu tratament el redüiss i livèll di ormone maschil (androgeni) in del corp, che pœden rallentar o fermà la cressita del cancher de prostata.
El pœl vesser drovad sol o in combinazion con olter tratament.
5. Chimioterapia: Chestu tratament al dupera di drogh per copà i cellule cancerose.
El pœl vesser drovad per el cancher de prostata avanzad che s'è spantegad in olter part del corp.
6. Immunoterapia:'sto tratament el jut el sistema immunitari a combatt el cancher.
El pœl vesser drovad per el carcinoma de prostata avanzad qe l'ha minga respondud a olter tratament.
7. Terapia mirada: chesta terapia la mira a geni o proteine specifich qe i juten i cellule cancerose a cresser e a sopravviver.
El pœl vesser drovad per el carcinoma de prostata avanzad qe l'ha minga respondud a olter tratament.
8. Crioterapia:'sto tratament el dupera el frecc estrem per congelare e copar i cellule cancerose.
El pœl vesser drovad per el cancher de prostata in fase iniziala o per el cancher qe l"è tornad dopo olter tratament.
9. Ultrason focalizad de alta intensità (HIFU): chestu tratament el dupera ond sonor de alta frequenza per scaldà e distrügg i cellule cancerose.
El pœl vesser drovad per el cancher de prostata in fase iniziala o per el cancher qe l"è tornad dopo olter tratament.
10. Aspettà attent: Chestu approcch al implica un monitoragg attent del cancher cun control e test regolàr, ma minga cumincià el trattament a men che i sintom i comparissen o cambien.
Pœu vesser adatad per i omm de età plu vegia cun un cancher de prostata a cress lenta e olter condizion de salute seri.
L'è important discuter de tucc i opzion de cura cun un grupp de cura per determinà la mior cura per ogni cas individual.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Disclaimer: medegh']
['Chestu sit web l"è furnid dumà per scopi educatif e informativ e l"è minga un cunsigli medich o un servizzi prufessiunal.']
["I informaziun furnid i g'han minga de vess drovad per diagnosticar o curar un prublema de salute o una malatia, e quei qe i cercan un cunsili medegh personal i g'han de consultar un medegh licenziad."]
['Per piasè, tegnì cont che la red neural che la genera rispost ai dumand l"è minga precisa quand che se tratta de numer, per esempi, el numer de gent che g\'ha una malattia precisa.']
["Cercà semper el cunsili del tò dutur o de un olter fornitur de sanità qualificaa in su una cundizion medica. Mai ignorà el cunsili medich prufessional o ritardà in de cercàll per via de un quaicoss che te gh'heet legiu in su'sto sit web. Se te penset de avègh una emergenza medica, ciama el 911 o va in del pronto soccors püssee vesin subit."]
['Disclaimer: copyright']
["El Digital Millennium Copyright Act del 1998, 17 U.S.C. § 512 (el DMCA) el dà recurs ai proprietari de copyright che creden che el material che 'l compariss in su Internet el infrange i sò dirit sota la legg di copyright di Stat Ünì. "]
["Se te credet de bona fede che un qualcun contegnü o material metüü a disposiziun in cunnessión cun el noster sit web o i noster servizzi infrang el tò copyright, te (o el tò agent) pudet mandà un avisi che dumanda che el contegnü o material vegn tolt, o che l'access a lü el vegn blocaa."]
['I avisi i g\'ha de vess mandaa per scrit per email (varda la sezion "Cuntatt" per l\'indirizz email).']
["La DMCA la dis che la tua notifica de presunta violazion del copyright la gh'ha de cuntà la seguent informazion: (1) descrizion de l'opera protetta dal copyright che l'è oget de la presunta violazion; (2) descrizion del presunt contegnud che 'l viola e informazion suficent per permetem de localizà el contegnud; (3) informazion de contatt per ti, cumprend el to indirizz, numer de telefon e indirizz email; (4) una declarazion de ti che te gh'heet bona fede che 'l contegnud de la manera reclamada l'è minga autorizzaa del proprietari del copyright, o del sò agent, o de la funzion de nissuna legg; "]
['(5) una declaraziun de ti, firmada sota pena de spergiur, che l\'informaziun in de la notificaziun l"è precisa e che te gh\'heet l\'autorità per fà valer i dirit de autor che se pretend de vess violaa;']
['e (6) una firma fisica o eletronica del proprietari del copyright o de una persona autorizada a agì per el proprietari del copyright.']
['Se no se inclüden tücc i infurmaziun sura indicà pœden causà un ritard in del processà la tua denuncia.']
['cuntatt']
['Per piasè mandem una mail cun qual-sa-vöör dumanda/suggeriment.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Circa']
['BioMedLib dupera computer automatizzads (algoritmi de machine-learning) per generar coppie de dumanda e risposta.']
['Cominciom con 35 milion de publicazion biomediche de PubMed/Medline.']
